Acute myeloid leukaemia drug Xospata nears getting insurance benefits

Korea Biomedical Review

3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step closer to winning health insurance benefits.

On Friday, the Health Insurance Review and Assessment Service (HIRA) released the result of the drugs benefit appraisal committee’s meeting on Xospata’s eligibility for reimbursement.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder